Screener
Neurocrine Biosciences NBIX Q4 2025 Annual earnings
Reported February 11, 2026 · After market close
Revenue$805.5MBeat by $15.0M
EPS$1.88Beat by $0.08
Revenue estimate$790.5M
EPS estimate$1.80
Next report
Oct 27, 2026 (in a month)Revenue estimate$1.0B
EPS estimate$2.59
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Neurocrine Biosciences report Q4 2025 earnings?
- Neurocrine Biosciences (NBIX) reported Q4 2025 earnings on February 11, 2026 after market close.
- What were Neurocrine Biosciences's Q4 2025 revenue and EPS?
- Neurocrine Biosciences reported revenue of $805.5M and eps of $1.88 for Q4 2025.
- Did Neurocrine Biosciences beat estimates in Q4 2025?
- Revenue beat the consensus estimate of $790.5M by $15.0M. EPS beat the consensus estimate of $1.80 by $0.08.
- How did Neurocrine Biosciences's Q4 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 28.3% from $627.7M a year earlier and eps grew 88.0% from $1.00.
- Where can I find Neurocrine Biosciences's Q4 2025 SEC filings?
- You can read the 8-K earnings release (0000914475-26-000006) and the 10-K periodic report (0000914475-26-000007) directly on SEC EDGAR. The filing index links above go to sec.gov.
